Technical Analysis for ACW - Actinogen Medical Ltd
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 3.23% | |
Narrow Range Bar | Range Contraction | 3.23% | |
Doji - Bullish? | Reversal | 3.23% | |
Wide Bands | Range Expansion | 3.23% | |
Gapped Down | Weakness | 3.23% | |
50 DMA Support | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 5 hours ago |
Down 3% | about 5 hours ago |
Down 2% | about 5 hours ago |
Down 1% | about 5 hours ago |
50 DMA Resistance | about 6 hours ago |
Free Daily (Stock) Chart Reading
Actinogen Medical Ltd Description
Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Disease Diseases Safety Diabetes Psychiatric Diagnosis Psychiatry Alzheimer's Disease Dementia Parkinson Degenerative Disease Parkinson's Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.075 |
52 Week Low | 0.015 |
Average Volume | 3,687,363 |
200-Day Moving Average | 0.028 |
50-Day Moving Average | 0.032 |
20-Day Moving Average | 0.034 |
10-Day Moving Average | 0.032 |
Average True Range | 0.003 |
RSI (14) | 39.39 |
ADX | 16.14 |
+DI | 18.764 |
-DI | 22.737 |
Chandelier Exit (Long, 3 ATRs) | 0.046 |
Chandelier Exit (Short, 3 ATRs) | 0.040 |
Upper Bollinger Bands | 0.039 |
Lower Bollinger Band | 0.029 |
Percent B (%b) | 0.22 |
BandWidth | 30.678 |
MACD Line | -0.001 |
MACD Signal Line | 0.000 |
MACD Histogram | -0.0006 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.033 | ||||
Resistance 3 (R3) | 0.033 | 0.033 | 0.033 | ||
Resistance 2 (R2) | 0.033 | 0.032 | 0.033 | 0.033 | |
Resistance 1 (R1) | 0.032 | 0.032 | 0.032 | 0.032 | 0.033 |
Pivot Point | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 |
Support 1 (S1) | 0.030 | 0.031 | 0.030 | 0.030 | 0.029 |
Support 2 (S2) | 0.030 | 0.030 | 0.030 | 0.029 | |
Support 3 (S3) | 0.029 | 0.030 | 0.029 | ||
Support 4 (S4) | 0.029 |